Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business dayGet my quote

Talvey vs Tecvayli: how two US-approved medicines for multiple myeloma compare

Creator: Reserve Meds
Published: 2026-10-17

A side-by-side guide for families in the Gulf, built from the US FDA labels, Gulf drug registers and official sources.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026. Facts on this page come from the current US prescribing information for each medicine.

Talvey vs Tecvayli: the short answer

Talvey and Tecvayli are both US FDA-approved for multiple myeloma, but for different patients and in different ways. No trial has compared them head to head. Your specialist decides which, if either, fits. Reserve Meds is a digital health company. We do not diagnose or prescribe.

Condition: multiple myeloma.
Main difference: They are given the same way, as injections under the skin after step-up doses with hospital monitoring, but they hit different targets and have different label populations.
Head-to-head evidence: none in either US label.
Price: Quote on request.

Talvey and Tecvayli side by side

The table summarizes each current US label. Labels are long; your specialist and hospital pharmacy work from the full text.

Feature	Talvey	Tecvayli
Generic name	talquetamab-tgvs^[2]	teclistamab-cqyv^[3]
Type of medicine	bispecific antibody (T-cell engager) that targets GPRC5D on myeloma cells and CD3 on T cells^[2]	bispecific antibody (T-cell engager) that targets BCMA on myeloma cells and CD3 on T cells^[3]
US-approved for	Adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This is an accelerated approval based on response rate and durability of response.^[2]	Adults with relapsed or refractory multiple myeloma, in two settings: with daratumumab and hyaluronidase-fihj after at least one prior line including a proteasome inhibitor and an immunomodulatory agent, or alone after at least four prior lines including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.^[3]
First US approval (year on the label)	2023^[2]	2022^[3]
How it is given	Injection under the skin by a healthcare provider. Treatment starts with step-up doses, then continues at 0.4 mg/kg once weekly or 0.8 mg/kg every 2 weeks.^[2]	Injection under the skin by a healthcare provider. Treatment starts with step-up doses. Used alone, it continues at 1.5 mg/kg once weekly, and the dose interval may be extended to every two weeks for patients with a complete response or better for at least 6 months.^[3]
Where and what to expect	Patients should be hospitalized for 48 hours after each dose in the step-up schedule.^[2]	Patients should be hospitalized for 48 hours after step-up dose 1 and step-up dose 2, and stay near a healthcare facility with daily monitoring for 48 hours after the first treatment dose.^[3]
Boxed warning	Yes. Cytokine release syndrome and neurologic toxicity including ICANS. Available only through the TECVAYLI and TALVEY REMS restricted program.^[2]	Yes. Cytokine release syndrome and neurologic toxicity including ICANS. Available only through the TECVAYLI and TALVEY REMS restricted program.^[3]

About multiple myeloma and these two medicines

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell that is part of the immune system. In time, myeloma cells collect in the bone marrow and in the solid parts of bones.^[1]

Talvey and Tecvayli are both bispecific T-cell engaging antibodies: each binds CD3 on T cells and a protein on myeloma cells, and in laboratory studies this led T cells to destroy myeloma cells. Talvey targets GPRC5D. Tecvayli targets BCMA. Both share one US safety program, the TECVAYLI and TALVEY REMS.^{[2, 3]}

The main difference

They are given the same way, as injections under the skin after step-up doses with hospital monitoring, but they hit different targets and have different label populations. Talvey is approved after at least four prior lines. Tecvayli is approved alone after at least four prior lines, or with daratumumab and hyaluronidase-fihj after at least one prior line. Their common side effects also differ: the Talvey label lists taste changes, nail and skin disorders, weight loss and dry mouth.^{[2, 3]}

The evidence behind each approval

Talvey. MonumenTAL-1 was a single-arm, open-label study. The label reports response rate and duration of response in 187 patients who had at least four prior lines and no prior T-cell redirection therapy. It also reports results in 32 patients who had received prior T-cell redirection therapy, 81% of whom had received CAR-T therapy.^[2]

Tecvayli. MajesTEC-3 was a randomized, open-label study in 587 patients after one to three prior lines. Tecvayli with daratumumab and hyaluronidase-fihj was compared with DPd or DVd, and the label reports a statistically significant improvement in progression-free survival and overall survival. MajesTEC-1 was a single-arm study of Tecvayli alone in 110 patients, based on overall response rate.^[3]

No head-to-head trial. Neither US label reports a study that compared Talvey directly with Tecvayli. The trials above enrolled different patients at different stages, so their results cannot be set side by side to decide which medicine works better.

Using one after the other

The Talvey label reports results in 32 patients who had received prior T-cell redirection therapy, 25% of them a bispecific antibody and 94% of them treatment directed at BCMA. Neither label describes using the two together. Your specialist decides the order of treatments.^{[2, 3]}

Safety: what the labels warn about

Both labels list warnings that the treating team monitors. The boxed warning row in the table above is the most serious level of warning on a US label.

Talvey: common side effects listed on the label include fever, cytokine release syndrome, taste changes (dysgeusia), nail disorders, musculoskeletal pain, skin disorders, rash, fatigue, weight loss and dry mouth.^[2]
Tecvayli: common side effects listed on the label include fever, cytokine release syndrome, musculoskeletal pain, injection site reactions, fatigue, upper respiratory tract infection, nausea and headache (when used alone).^[3]

Availability in the Gulf

Talvey: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[4, 5]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Iraq
Tecvayli: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[4, 5]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Iraq

How families in the Gulf can access Talvey or Tecvayli

If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks it, but local supply is usually the fastest route and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.^{[6, 7]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

A US safety program applies. In the US, Talvey and Tecvayli are available only through the TECVAYLI and TALVEY REMS, a restricted program.^{[2, 3]} The treating hospital must be able to give the step-up doses with hospital monitoring as the label describes.

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only and we do not choose between medicines.

Ask us about Talvey or Tecvayli

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

Which is better, Talvey or Tecvayli?

There is no head-to-head trial, so no one can say from the evidence that one is better. They are approved for different patients and are given differently. Your specialist decides which fits, based on prior treatment, test results and overall health.

What is the main difference between Talvey and Tecvayli?

Are Talvey and Tecvayli available in Saudi Arabia or the UAE?

Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list.

How can a family in the Gulf get Talvey or Tecvayli?

Ask the treating hospital about local supply first. If the medicine is not registered, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.

How much do these medicines cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds choose the medicine?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or choose between medicines. Your specialist and hospital make the medical decisions.

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.